

## E-AUCTION SALE NOTICE

Under Insolvency and Bankruptcy Code, 2016

**R. V. STEELS AND POWER PRIVATE LIMITED - IN LIQUIDATION**

Reg. Off.: 4/2, Second Street, B.N. Road, T. Nagar, Chennai, 600017

Date and Time of E-Auction: Monday, 27<sup>th</sup> January, 2025 from 12:00 PM to 01:00 PM

(With Unlimited Extension of 5 Minutes)

E-Auction Sale of Asset by R.V. STEELS AND POWER PRIVATE LIMITED (In Liquidation) will be conducted on “As is where is basis”, “As is what is basis”, “Whatever there is basis”, “No recourse basis”.

Asset	Reserve Price (Rs.)	Earnest Money Deposit (Rs.)	Bid Increment Amount (Rs.)
Freehold Vacant Land admeasuring 3.5 Acres situated at Kannanthangal/Vadagal - C Village, Sriperumbudur Taluk, Kancheepuram District having various survey no. i.e. 423/1B, 431/6A10, 431/6A11, 431/6A3,431/6A4, 431/6A5, 431/6A6, 431/6A7, 431/6A8, 431/6A9, 431/6B, 431/6C, 431/6D, 422/12, 422/13, 422/5, 431/6A2	96,26,000	9,62,600	1,00,000

### Terms and Condition of the E-auction are as under:

- 1) The description of assets and terms & conditions of the E-Auction Sale are provided in the E-Auction Sale Process Memorandum available on the website of approved service provider M/s E-Procurement Technologies Limited (Auction Tiger) - <https://ncltauction.auctiontiger.net> For clarifications contact: Mr. Praveen Thevar at +91 97227 78828 or email at [Praveen.thevar@auctiontiger.net](mailto:Praveen.thevar@auctiontiger.net) or [nclt@auctiontiger.net](mailto:nclt@auctiontiger.net)
- 2) The intending bidders are required to deposit Earnest Money Deposit (EMD) amount by 25<sup>th</sup> January, 2025 through DD/NEFT/RTGS in the account of “R.V. Steels and Power Private Limited - In Liquidation” having Account Number 919020053050952, Axis Bank, Branch: Kolathur, IFSC Code: UTIB0001859.
- 3) The Liquidator has the absolute right to accept or reject any or all offer(s) or adjourn/postpone/cancel the E-Auction or withdraw any property or portion thereof from the auction proceeding at any stage without assigning any reason thereof.

Sd/-

**Lalit Kumar Dangi**

**Liquidator of R.V. Steels and Power Private Limited (In Liquidation)**

**IBBI Regn. No: IBBI/IPA-001/IP-PO1821/2019-2020/12859**

**Registered Address:** - 104, M.K Bhavan, 300 Shahid Bhagat Singh Road, Fort, Mumbai City - 400001, Maharashtra

**Correspondence Address:** - B-526, Chintamani Plaza, Near W.E. Highway Metro Station, Andheri Kurla Road, Andheri (East), Mumbai- 400099

Email: - [liquidator.rvsteel@gmail.com](mailto:liquidator.rvsteel@gmail.com), [lalitikumardangi.ip@gmail.com](mailto:lalitikumardangi.ip@gmail.com)  
Contact No.: - +91-9769606009

Date: - 02<sup>nd</sup> January, 2025  
Place: - Mumbai



## Health Matters

# Successful clinical trials for treating Alzheimer's

Researchers at the Warren Centre for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a phase I single ascending dose clinical trial of VU319, a drug for memory loss in people with Alzheimer's disease and schizophrenia.

"This milestone highlights Vanderbilt's ability to drive discovery from research to clinical impact. The success of VU319 exemplifies how collaboration and innovation can bring real hope to patients and families facing Alzheimer's and other neurodegenerative diseases," said provost and vice chancellor for Academic Affairs Cybele Raver.

John Kuriyan, dean of basic sciences and University Distinguished Professor of Biochemistry and Chemistry, agreed, adding, "The successful phase I trial of VU319 marks a potentially transformative step in drug development for Alzheimer's, showcasing Vanderbilt's capacity to translate fundamental research into therapeutic discovery that brings the hope of real clinical impact."

VU319 is the first Vanderbilt end-to-end drug discovery effort, starting from the earliest basic science research through human clinical trials. The effort spanned a high-throughput screening hit-to-candidate selection to completion of a clinical trial.

"After more than a decade of basic and translational research, the WCNDDD was finally able to disclose how VU319, a unique M1 PAM, was discovered and profiled," said Craig Lindsley, executive director of the WCNDDD and University Professor of Pharmacology, Biochemistry and Chemistry who holds the William K. Warren, Jr. Chair in Medicine.

In addition to treating Alzheimer's disease, which affects roughly 6.9 million people over age 65 and has no known cure, VU319 has shown potential to treat memory loss in schizophrenia, prion diseases, Rett syndrome, vascular dementia, and Lewy body dementia.

"Funding from the National Institute of Mental Health

allowed the WCNDDD to discover and develop VU319. An important philanthropic gift from the William K. Warren Foundation then enabled us to partner with DavosPharma to conduct critical early-stage studies and earn approval from the FDA as an investigational new drug, paving the way for the Alzheimer's Association award to Dr. Paul Newhouse for the phase I trial," Lindsley said. "Overall, it has been incredibly rewarding to drive a programme from the most basic discovery stage and translate it into human clinical testing, all at Vanderbilt."

The neurotransmitter acetylcholine is responsible for learning and memory, but in Alzheimer's and other neurodegenerative diseases, such as schizophrenia, it is one of the first that stops working and disables neurons from functioning properly. VU319, an M1 positive allosteric modulator, increases the efficacy of the endogenous neurotransmitter acetylcholine at the M1 receptor, acting as a dimmer switch to "turn-up" the gain on the receptor selectively, providing the best possible therapeutic index.

In the human trial performed at Vanderbilt by Dr. Paul Newhouse, professor of psychiatry and pharmacology, director of the Vanderbilt Center for Cognitive Medicine, and clinical core director of the Vanderbilt Memory and Alzheimer's Center, the researchers saw signs of target engagement at the highest dose of the treatment that was tested and saw no side effects typical of other drugs working on the same area of the brain.



# Sunscreen prototype based on radiative cooling

Wearing sunscreen is important to protect your skin from the harmful effects of UV radiation but doesn't cool people off. However, a new formula protects against both UV light and heat from the sun using radiative cooling. The prototype sunblock kept human skin up to 11 degrees Fahrenheit (6 degrees Celsius) cooler than bare skin, or around 6 degrees Fahrenheit (3 degrees Celsius) cooler than existing sunscreens.

Radiative cooling involves either reflecting or radiating heat away from something, cooling whatever's underneath. It is already used to create cooling fabrics and coatings that could both cool and heat homes, among other applications.

Some passive radiative cooling technologies rely on an ingredient called titanium dioxide (TiO2) because the whitish substance reflects heat.

TiO2 particles are also used in mineral sunscreens to reflect UV light, but the particles aren't the right size to produce a cooling effect.

So, Rufan Zhang and colleagues wanted to tune the size of TiO2 nanoparticles to create a sunscreen that works both as a UV protector and a radiative cooler.

The team created their sunblock by combining six ingredients: TiO2 nanoparticles, water, ethanol, moisturizing cream, pigments, and a common silicone polymer used in cosmetics called

polydimethylsiloxane.

By carefully adjusting the sizes of the TiO2 nanoparticles, they produced a material that reflects both UV light and solar heat, imparting the cooling ability.

The new formulation demonstrated an SPF of about 50, water resistance and continued efficacy after 12 hours of simulated sunlight exposure with a xenon lamp.

Additionally, when applied to both animal and human skin, the product didn't cause irritation.

In tests on people in a hot and humid outdoor environment, the new radiative cooling sunscreen was found to keep the participants' skin up to 10.8 F (6.0 C) cooler than bare skin, and up to 11.0 F (6.1 C) cooler than commercially available sunscreens.

The formulation is inexpensive, costing only \$0.92 for 10 grams of the mixture -- on par with sunblocks already on the market.

The researchers say their sunscreen prototype exhibits promising commercial potential, especially as temperatures in the summer continue to rise.



# Stress increases tremors in Parkinson's patients

The standard medication levodopa does not always work against tremors in Parkinson's disease, especially in stressful situations. Propranolol, however, does work during stress, providing insight into the role of the stress system in tremors. MRI scans reveal that propranolol directly inhibits activity in the brain circuit that controls tremors. Doctors may consider this medication when levodopa is ineffective.

People with Parkinson's disease report that tremors worsen during stressful situations. "Tremors act as a sort of barometer for stress; you see this in all people with Parkinson's," says neurologist Rick Helmich from Radboud university medical center. The commonly used drug levodopa usually helps with tremors, but it tends to be less effective during stress, when tremors are often at their worst. Helmich and his team wanted to investigate whether a medication targeting the stress system could help and how this effect of stress on tremors works in the brain.

The medication in question, propranolol, is a beta-blocker that inhibits the action of stress hormones. It was developed for high blood pressure and heart arrhythmias, has been around for a long time, and is already used as a standard treatment for essential tremor -- a condition in which people experience tremors without other neurological symptoms. There were already indications that propranolol might reduce tremors in Parkinson's, but until now, no thorough

research has explored its potential effects. Helmich and his team studied 27 people with Parkinson's who experienced tremors. They were given propranolol on one day and a placebo on another day. A device on their hands measured the intensity of their tremors, while an MRI scan mapped brain activity. This was done both at rest and during a task involving stressful mathematical calculations. The stress response was measured by pupil size and heart rate, both of which increased during the calculations. As expected, without medication, tremors worsened during stress. The study showed that propranolol reduced tremors both at rest and during stress. The MRI scans revealed how this works: after taking the medication, the brain circuit responsible for tremors showed less activity. Helmich explains: "We know that abnormalities in systems like the dopamine system cause tremors. Based on our study, we now think that the stress hormone noradrenaline acts as an amplifier, which increases tremor intensity in the brain's movement area. Propranolol inhibits this amplifying effect and thus reduces symptoms."

It surprised the researchers that propranolol also worked to reduce tremors at rest. "Apparently, our stress system is occasionally active, even at rest," says researcher Anouk van der Heide. "This changes how alert someone is and leads to spontaneous fluctuations in tremors. We previously thought that the stress hormone system was only active



under stress, but apparently, that's too simplistic. It also plays a role at rest."

Helmich already prescribes propranolol for some Parkinson's patients. "The most effective medication for Parkinson's is levodopa. It not only helps with tremors but also with other symptoms, so that's what we start with. However, in about forty percent of patients, it is not effective against tremors. In that case, we first increase the dose, but if that doesn't work, propranolol is an option. However, we

# First dual chamber leadless pacemaker implanted in child

UC Davis director of paediatric electrophysiology Dan Cortez has set another world record: He is the first to implant a dual chamber leadless pacemaker in a child. A 13-year-old patient was referred to the UC Davis paediatric electrophysiology clinic for presyncope, a feeling of lightheadedness or dizziness without actually fainting, after being monitored for years for congenital complete heart block.


Pacemakers are typically placed in children with congenital complete heart block, a rare condition that can lead to sudden death and affects 1 in about 15,000 to 22,000 children. Congenital complete heart block may occur due to repaired congenital heart disease or genetic predisposition. It can also be acquired from exposure to certain maternal antibodies.

After serial electrocardiograms and Holter monitors showed progressively lower average heart rates, Cortez talked with the

Houston Methodist researchers have discovered that certain components of so-called "good" cholesterol - high-density lipoproteins (HDL) - may be associated with an increased prevalence of cardiovascular disease.

Led by Henry J. Pownall, PhD, professor of biochemistry in medicine at the Houston Methodist Research Institute, and Khurram Nasir, MD, MPH, a cardiologist and division chief of cardiovascular prevention and wellness at Houston Methodist, the research team is using innovative methods to investigate the role of certain properties of HDL in heart health.

"During routine checkups, adults have their cholesterol levels tested, which includes both 'bad' (LDL) and 'good' (HDL) cholesterol," said Pownall, who is the corresponding author of a study. "Not all cholesterol, however, is born the same. What is not commonly recognised is that each type of cholesterol has two forms - free cholesterol, which is active and involved



in cellular functions, and esterified, or bound, cholesterol, which is more stable and ready to be stored in the body. Too much free cholesterol, even if it is in HDL, could contribute to heart disease."

In pre-clinical studies, the research team discovered that HDL with a high content of free cholesterol is likely dysfunctional. To validate their findings and prove their hypothesis, they are currently at the halfway point of the NIH-funded Houston Heart Study in which they will be studying 400 patients with a range of plasma HDL concentrations. Pownall

and Nasir are the co-PIs of the study.

"The most surprising finding from our study thus far is that there is a strong link between the amount of free cholesterol in HDL and how much of it accumulates in white blood cells called macrophages, which can contribute to heart disease," Pownall said.

While it was previously thought that the transfer of free cholesterol to HDL was beneficial for heart health by removing excess cholesterol from tissues, Pownall said their data shows that in the context of high plasma HDL concentrations, the reverse is true, wherein free

cholesterol transfer from HDL to the white blood cells in blood and tissues could actually raise one's risk for cardiovascular disease. The researchers say once they reach their immediate goal of showing that excess free cholesterol in HDL is associated with excess cardiovascular disease, they plan to develop new diagnostics and treatments for managing heart disease, as well as use HDL-free cholesterol as a biomarker to identify patients requiring HDL-lowering therapies.

"We anticipate being able to reach our first goal in less than three years, as there are some known drugs that affect free cholesterol in pre-clinical models, so this could be tested in humans if our tests justify the use of these known therapeutics," Pownall said.

If they are successful, Pownall proposes that they could potentially be able to apply what they learn to patients in a clinical setting as quickly as six years from now.

# Good cholesterol can become harmful: Research

E-AUCTION SALE NOTICE			
Under Insolvency and Bankruptcy Code, 2016			
R. V. STEELS AND POWER PRIVATE LIMITED - IN LIQUIDATION			
Reg. Off.: 4/2, Second Street, B.N. Road, T. Nagar, Chennai, 600017			
Date and Time of E-Auction: Monday, 27 <sup>th</sup> January, 2025 from 12:00 PM to 01:00 PM (With Unlimited Extension of 5 Minutes)			
E-Auction Sale of Asset by R.V. STEELS AND POWER PRIVATE LIMITED (In Liquidation) will be conducted on "As is where is basis", "As is what is basis", "Whatever there is basis", "No recourse basis".			
Asset	Reserve Price (Rs.)	Earnest Money Deposit (Rs.)	Bid Increment (Rs.)
Freehold Vacant Land admeasuring 3.5 Acres situated at Kannanhangal/Vadagal - C Village, Sniperumbudur Taluk, Kancheepuram District having various survey no. i.e. 423/15, 431/6A/10, 431/6A/11, 431/6A/3, 431/6A/4, 431/6A/5, 431/6A/6, 431/6A/7, 431/6A/8, 431/6A/9, 431/6A, 431/6C, 431/6D, 422/12, 422/13, 422/5, 431/6A/2	96,26,000	9,62,600	1,00,000

Terms and Condition of the E-Auction are as under:

- The description of assets and terms & conditions of the E-Auction Sale are provided in the E-Auction Sale Process Memorandum available on the website of approved service provider M/S E-Procurement Technologies Limited (Auction Tiger) - <https://indiauction.auctiontiger.net>. For clarifications contact: Mr. Praveen Thevar at +91 97227 78828 or email at Praveen.thevar@auctiontiger.net or nct@auctiontiger.net
- The intending bidders are required to deposit Earnest Money Deposit (EMD) amount by 25th January, 2025 through DD/NEFT/RTGS in the account of "R.V. Steels and Power Private Limited - In Liquidation" having Account Number 919020053050952, Axis Bank, Branch: Kolathur, IFSC Code: UTIB0001859.
- The Liquidator has the absolute right to accept or reject any or all offer(s) or adjourn/postpone/cancel the E-Auction or withdraw any property or portion thereof from the auction proceeding at any stage without assigning any reason thereof.

Sd/-  
Date: 02<sup>nd</sup> January, 2025  
Place: Mumbai

Lalit Kumar Dangli  
Liquidator of R.V. Steels and Power Private Limited (In Liquidation)  
IBBI Regn. No. IBBI/PA-01/IP-P01821/2019-2020/12859  
Registered Address: - 104, M.K Bhavan, 300 Shahid Bhagat Singh Road, Fort, Mumbai City - 400001, Maharashtra  
Correspondence Address: - B-526, Chintamani Plaza, Near W.E. Highway Metro Station, Andheri Kurla Road, Andheri (East), Mumbai- 400099  
Email: liquidator.rvsteel@gmail.com, lalitkumardangli@gmail.com Contact No.: +91-9796960009